Gene manipulation to enhance MIBG-targeted radionuclide therapy.
The goal of targeted radionuclide therapy is the deposition in malignant cells of sterilizing doses of radiation without damaging normal tissue. The radiopharmaceutical [(131)I]meta-iodobenzylguanidine ([(131)I]MIBG) is an effective single agent for the treatment of neuroblastoma. However, uptake of the drug in malignant sites is insufficient to cure disease. A growing body of experimental evidence indicates exciting possibilities for the integration of gene transfer with [(131)I]MIBG-targeted radiotherapy.
Mairs
Robert J
RJ
Targeted Therapy Group, Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, University of Glasgow. r.mairs@beatson.gla.ac.uk
Fullerton
Natasha E
NE
Cosimo
Emilio
E
Boyd
Marie
M
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods; D018390:Gene Targeting / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009447:Neuroblastoma / Q000235:genetics* / Q000532:radiotherapy*; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000235:genetics*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods*
D050484:Norepinephrine Plasma Membrane Transport Proteins; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine